中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1929-1933

Prediction and treatment of lymph node metastasis of intrahepatic cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2021.08.040
  • 1.

    The First Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China

  • 2.

    Department of Hepatopancreatobiliary Surgery, The First Hospital of Shanxi Medical University, Taiyuan 030000, China

Research funding:

Shanxi Scholarship Council of China (2017-113)

  • Received Date: 2021-01-02
  • Accepted Date: 2021-01-27
  • Published Date: 2021-08-20
    Abstract
  • Intrahepatic cholangiocarcinoma (ICC) is the second largest primary liver cancer, and lymph node metastasis of ICC is commonly observed. Lymph node metastasis not only affects the prognosis of patients, but also determines the choice of treatment regimen. This article summarizes related articles on ICC in China and globally and elaborates on the serological markers and imaging indicators for predicting lymph node metastasis of ICC, the controversy over the selection of lymph node resection and postoperative adjuvant treatment for patients eligible for radical resection, and the research advances in neoadjuvant therapy for patients with advanced ICC who cannot undergo surgery, so as to provide theoretical support for the treatment of ICC patients and the prediction of lymph node metastasis.

     

    • FullText(HTML)
    • References(57)
  • [1]
    YEESOONSANG S, MCNEIL E, VIRANI S, et al. Trends in incidence of two major subtypes of liver and bile duct cancer: Hepatocellular carcinoma and cholangiocarcinoma in Songkhla, southern Thailand, 1989-2030[J]. J Cancer Epidemiol, 2018, 2018: 8267059. DOI: 10.1155/2018/8267059.
    [2]
    MENG ZW, HAN SH, ZHU JH, et al. Risk factors for cholangiocarcinoma after initial hepatectomy for intrahepatic stones[J]. World J Surg, 2017, 41(3): 835-843. DOI: 10.1007/s00268-016-3752-2.
    [3]
    MORINE Y, SHIMADA M. The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics[J]. J Gastroenterol, 2015, 50(9): 913-927. DOI: 10.1007/s00535-015-1071-2.
    [4]
    JI GW, ZHU FP, ZHANG YD, et al. A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma[J]. Eur Radiol, 2019, 29(7): 3725-3735. DOI: 10.1007/s00330-019-06142-7.
    [5]
    CHANG ME, LEI HJ, CHEN MH, et al. Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center[J]. J Chin Med Assoc, 2017, 80(3): 140-146. DOI: 10.1016/j.jcma.2016.09.010.
    [6]
    YOH T, HATANO E, SEO S, et al. Preoperative criterion identifying a low-risk group for lymph node metastasis in intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2018, 25(6): 299-307. DOI: 10.1002/jhbp.552.
    [7]
    HAMMAD AY, BERGER NG, EASTWOOD D, et al. Is radiotherapy warranted following intrahepatic cholangiocarcinoma resection? The impact of surgical margins and lymph node status on survival[J]. Ann Surg Oncol, 2016, 23(Suppl 5): 912-920. DOI: 10.1245/s10434-016-5560-1.
    [8]
    WANG L, LIN ZG, YANG T, et al. A multicenter retrospective study on clinical value of lymph node dissection in the radical resection of intrahepatic cholangiocarcinoma[J]. Chin J Dig Surg, 2020, 19(1): 72-80. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.012.

    王垒, 林自国, 杨田, 等. 淋巴结清扫在肝内胆管癌根治术中临床价值的多中心回顾性研究[J]. 中华消化外科杂志, 2020, 19(1): 72-80. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.012.
    [9]
    BRAUER DG, FIELDS RC, TAN BR Jr, et al. Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma[J]. HPB (Oxford), 2018, 20(5): 470-476. DOI: 10.1016/j.hpb.2017.11.010.
    [10]
    ZHANG XF, XUE F, DONG DH, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis[J]. Ann Surg, 2020. DOI: 10.1097/SLA.0000000000003788.[Online ahead of print]
    [11]
    NAVARRO JG, LEE JH, KANG I, et al. Prognostic significance of and risk prediction model for lymph node metastasis in resectable intrahepatic cholangiocarcinoma: Do all require lymph node dissection?[J]. HPB (Oxford), 2020, 22(10): 1411-1419. DOI: 10.1016/j.hpb.2020.01.009.
    [12]
    ASAOKA T, KOBAYASHI S, HANAKI T, et al. Clinical significance of preoperative CA19-9 and lymph node metastasis in intrahepatic cholangiocarcinoma[J]. Surg Today, 2020, 50(10): 1176-1186. DOI: 10.1007/s00595-020-01992-x.
    [13]
    SUI Y, GONG P, ZHANG XB, et al. Value of lymph node ratio in prognosis of patients with intrahepatic cholangiocarcinoma[J]. Chin J Hepatobiliary Surg, 2019, 25(4): 268-271. DOI: 10.3760/cma.j.issn.1007-8118.2019.04.007.

    隋毅, 巩鹏, 张贤彬, 等. 淋巴结阳性比率对于肝内胆管癌患者预后的价值[J]. 中华肝胆外科杂志, 2019, 25(4): 268-271. DOI: 10.3760/cma.j.issn.1007-8118.2019.04.007.
    [14]
    ZHU Y, MAO Y, CHEN J, et al. Preoperative computed tomography features of intrahepatic cholangiocarcinoma for predicting lymph node metastasis and overall survival[J]. J Comput Assist Tomogr, 2019, 43(5): 729-735. DOI: 10.1097/RCT.0000000000000922.
    [15]
    HARADA N, YOSHIZUMI T, YAMASHITA YI, et al. Impact and prediction of lymph node involvement in patients with intrahepatic cholangiocarcinoma after curative resection[J]. Anticancer Res, 2017, 37(7): 3763-3769. DOI: 10.21873/anticanres.11751.
    [16]
    XIA L, XIE YJ, ZHANG L, et al. Diagnosis and treatment of intrahepatic cholangiocarcinoma: Current status and thoughts[J]. J Clin Hepatol, 2020, 36(10): 2380-2385. DOI: 10.3969/j.issn.1001-5256.2020.10.048.

    夏龙, 夏医君, 张磊, 等. 肝内胆管细胞癌的诊疗现状与思考[J]. 临床肝胆病杂志, 2020, 36(10): 2380-2385. DOI: 10.3969/j.issn.1001-5256.2020.10.048.
    [17]
    HAN C, JIN LY, ZHAI TY, et al. Predictive value of preoperative serum tumor markers test for lymph node metastasis of intrahepatic cholangiocarcinoma[J]. Chin J Dig Surg, 2017, 16(5): 503-507. DOI: 10.3760/cma.j.issn.1673-9752.2017.05.013.

    韩超, 靳龙洋, 翟天宇, 等. 术前肿瘤标志物检测对肝内胆管细胞癌淋巴结转移的预测价值[J]. 中华消化外科杂志, 2017, 16(5): 503-507. DOI: 10.3760/cma.j.issn.1673-9752.2017.05.013.
    [18]
    YAMADA T, NAKANISHI Y, OKAMURA K, et al. Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma[J]. J Gastroenterol Hepatol, 2018, 33(9): 1626-1633. DOI: 10.1111/jgh.14124.
    [19]
    CHEN Q, ZHENG Y, ZHAO H, et al. The combination of preoperative D-dimer and CA19-9 predicts lymph node metastasis and survival in intrahepatic cholangiocarcinoma patients after curative resection[J]. Ann Transl Med, 2020, 8(5): 192. DOI: 10.21037/atm.2020.01.72.
    [20]
    WEI MY, ZHANG YY, GENG ZM, et al. Clinicopathological features and lymph node metastases characteristics of intrahepatic cholangiocarcinoma: A multicenter retrospective study (A report of 1321 cases)[J]. Chin J Dig Surg, 2018, 17(3): 257-265. DOI: 10.3760/cma.j.issn.1673-9752.2018.03.009.

    魏妙艳, 张园园, 耿智敏, 等. 肝内胆管癌临床病理特征及淋巴结转移特点的多中心回顾性研究(附1321例报告)[J]. 中华消化外科杂志, 2018, 17(3): 257-265. DOI: 10.3760/cma.j.issn.1673-9752.2018.03.009.
    [21]
    YAMAMOTO Y, TÜRKOǦLU MA, ARAMAKI T, et al. Vascularity of intrahepatic cholangiocarcinoma on computed tomography is predictive of lymph node metastasis[J]. Ann Surg Oncol, 2016, 23(Suppl 4): 485-493. DOI: 10.1245/s10434-016-5382-1.
    [22]
    ZHOU Y, ZHOU G, GAO X, et al. Apparent diffusion coefficient value of mass-forming intrahepatic cholangiocarcinoma: A potential imaging biomarker for prediction of lymph node metastasis[J]. Abdom Radiol (NY), 2020, 45(10): 3109-3118. DOI: 10.1007/s00261-020-02458-x.
    [23]
    TSILIMIGRAS DI, SAHARA K, PAREDES AZ, et al. Predicting lymph node metastasis in intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2021, 25(5): 1156-1163. DOI: 10.1007/s11605-020-04720-5.
    [24]
    MENG ZW, LIN XQ, ZHU JH, et al. A nomogram to predict lymph node metastasis before resection in intrahepatic cholangiocarcinoma[J]. J Surg Res, 2018, 226: 56-63. DOI: 10.1016/j.jss.2018.01.024.
    [25]
    XU L, YANG P, LIANG W, et al. A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma[J]. Theranostics, 2019, 9(18): 5374-5385. DOI: 10.7150/thno.34149.
    [26]
    HE K, HU ZM, RUAN JH, et al. Correlation of extracellular matrix protein 1 with primary intrahepatic cholangiocarcinoma and; lymph node metastasis[J]. Chin J Biomed Eng, 2015, 21(1): 40-44. DOI: 10.3760/cma.j.issn.1674-1927.2015.01.008.

    何坤, 胡泽民, 阮嘉后, 等. 细胞外基质蛋白1与原发性肝内胆管细胞癌及淋巴结转移的相关性分析[J]. 中华生物医学工程杂志, 2015, 21(1): 40-44. DOI: 10.3760/cma.j.issn.1674-1927.2015.01.008.
    [27]
    YAMAOKA R, ISHⅡ T, KAWAI T, et al. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis[J]. J Surg Oncol, 2018, 118(4): 664-674. DOI: 10.1002/jso.25192.
    [28]
    ZHU T, RAO JF, LIU CY, et al. Expression of CD90 in intrahepatic cholangiocellular carcinoma and its association with poor prognosis[J]. J Clin Hepatol, 2020, 36(2): 354-357. DOI: 10.3969/j.issn.1001-5256.2020.02.024.

    朱彤, 饶井芬, 刘承一, 等. CD90在肝内胆管细胞癌中的表达及其与患者预后不良的关系[J]. 临床肝胆病杂志, 2020, 36(2): 354-357. DOI: 10.3969/j.issn.1001-5256.2020.02.024.
    [29]
    YOH T, CAUCHY F, LE ROY B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: A multicenter study[J]. Surgery, 2019, 166(6): 975-982. DOI: 10.1016/j.surg.2019.06.025.
    [30]
    KIM SH, HAN DH, CHOI GH, et al. Oncologic impact of lymph node dissection for intrahepatic cholangiocarcinoma: A propensity score-matched study[J]. J Gastrointest Surg, 2019, 23(3): 538-544. DOI: 10.1007/s11605-018-3899-2.
    [31]
    ZENG YY, LI YT, ZHANG X. Effect of abdominal lymphadenectomy on prognosis of intrahepatic cholangiocarcinoma: A systematic review and Meta analysis[J]. Chin J Dig Surg, 2016, 15(4): 339-345. DOI: 10.3760/cma.j.issn.1673-9752.2016.04.007.

    曾永毅, 黎蕴通, 张翔. 腹腔淋巴结清扫对肝内胆管细胞癌预后影响的系统评价[J]. 中华消化外科杂志, 2016, 15(4): 339-345. DOI: 10.3760/cma.j.issn.1673-9752.2016.04.007.
    [32]
    ZHU MH, ZHANG XZ, HAN F, et al. Prognostic factors of radical resection on patients with intrahepatic cholangiocarcinoma and impact of abdominal lymph node dissection on prognosis[J]. Chin J Hepatobiliary Surg, 2020, 26(1): 48-52. DOI: 10.3760/cma.j.issn.1007-8118.2020.01.011.

    朱明辉, 张先舟, 韩风, 等. 腹腔淋巴结清扫范围对肝内胆管细胞癌患者根治性切除术预后的影响[J]. 中华肝胆外科杂志, 2020, 26(1): 48-52. DOI: 10.3760/cma.j.issn.1007-8118.2020.01.011.
    [33]
    ZHOU R, LU D, LI W, et al. Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis[J]. HPB (Oxford), 2019, 21(7): 784-792. DOI: 10.1016/j.hpb.2018.12.011.
    [34]
    HU J, CHEN FY, ZHOU KQ, et al. Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection[J]. Oncotarget, 2017, 8(69): 113817-113827. DOI: 10.18632/oncotarget.22852.
    [35]
    MIYATA T, YAMASHITA YI, YAMAO T, et al. Clinical benefits of lymph node dissection in intrahepatic cholangiocarcinoma: A retrospective single-institution study[J]. Anticancer Res, 2017, 37(5): 2673-2677. DOI: 10.21873/anticanres.11615.
    [36]
    KIZY S, ALTMAN AM, MARMOR S, et al. Surgical resection of lymph node positive intrahepatic cholangiocarcinoma may not improve survival[J]. HPB (Oxford), 2019, 21(2): 235-241. DOI: 10.1016/j.hpb.2018.08.006.
    [37]
    AMIN MB, GREENE FL, EDGE SB, et al. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67(2): 93-99. DOI: 10.3322/caac.21388.
    [38]
    KIM SH, HAN DH, CHOI GH, et al. Recommended minimal number of harvested lymph nodes for intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2021, 25(5): 1164-1171. DOI: 10.1007/s11605-020-04622-6.
    [39]
    JUTRIC Z, JOHNSTON WC, HOEN HM, et al. Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: A review of the National Cancer Database[J]. HPB (Oxford), 2016, 18(1): 79-87. DOI: 10.1016/j.hpb.2015.07.006.
    [40]
    ERVIN TJ, WEICHSELBAUM RR, FABIAN RL, et al. Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate[J]. Arch Otolaryngol, 1984, 110(4): 241-245. DOI: 10.1001/archotol.1984.00800300033007.
    [41]
    VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
    [42]
    LE ROY B, GELLI M, PITTAU G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7): 839-847. DOI: 10.1002/bjs.10641.
    [43]
    OTANI T, SAKATA J, KAMEYAMA H, et al. Surgical resection after gemcitabine plus cisplatin chemotherapy for intrahepatic cholangiocarcinoma with multiple lymph node metastases - Report of a case[J]. Gan To Kagaku Ryoho, 2016, 43(12): 1764-1766.
    [44]
    KONSTANTINIDIS IT, GROOT KOERKAMP B, DO RK, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone[J]. Cancer, 2016, 122(5): 758-765. DOI: 10.1002/cncr.29824.
    [45]
    SUMIYOSHI T, SHIMA Y, OKABAYASHI T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J]. World J Surg, 2018, 42(9): 2910-2918. DOI: 10.1007/s00268-018-4558-1.
    [46]
    EDELINE J, TOUCHEFEU Y, GUIU B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(1): 51-59. DOI: 10.1001/jamaoncol.2019.3702.
    [47]
    JAVLE M, LOWERY M, SHROFF RT, et al. Phase Ⅱ study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J]. J Clin Oncol, 2018, 36(3): 276-282. DOI: 10.1200/JCO.2017.75.5009.
    [48]
    PAN TT, WANG W, JIA WD, et al. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma[J]. Oncol Lett, 2017, 13(5): 2957-2964. DOI: 10.3892/ol.2017.5847.
    [49]
    HUANG M, HUANG B, LI G, et al. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell[J]. BMC Gastroenterol, 2018, 18(1): 169. DOI: 10.1186/s12876-018-0870-3.
    [50]
    FARIA J, de ANDRADE C, GOES AM, et al. Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation[J]. Biochem Biophys Res Commun, 2016, 478(1): 39-45. DOI: 10.1016/j.bbrc.2016.07.097.
    [51]
    SAEED A, PARK R, AL-JUMAYLI M, et al. Biologics, immunotherapy, and future directions in the treatment of advanced cholangiocarcinoma[J]. Clin Colorectal Cancer, 2019, 18(2): 81-90. DOI: 10.1016/j.clcc.2019.02.005.
    [52]
    ZHANG J, WU L, LIU J, et al. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: A case report and literature review[J]. Immunotherapy, 2020, 12(8): 555-561. DOI: 10.2217/imt-2019-0100.
    [53]
    LIU Z, LI S, ZENG J, et al. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1[J]. Life Sci, 2020, 257: 118068. DOI: 10.1016/j.lfs.2020.118068.
    [54]
    MOU H, YU L, LIAO Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: A case report[J]. BMC Cancer, 2018, 18(1): 1105. DOI: 10.1186/s12885-018-5021-2.
    [55]
    JING CY, FU YP, YI Y, et al. HHLA2 in intrahepatic cholangiocarcinoma: An immune checkpoint with prognostic significance and wider expression compared with PD-L1[J]. J Immunother Cancer, 2019, 7(1): 77. DOI: 10.1186/s40425-019-0554-8.
    [56]
    BANALES JM, CARDINALE V, CARPINO G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5): 261-280. DOI: 10.1038/nrgastro.2016.51.
    [57]
    ZHAO Z, MA J, WU K, et al. SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma[J]. Clin Transl Oncol, 2016, 18(9): 878-883. DOI: 10.1007/s12094-015-1449-x.
    • Relative Articles

  • Relative Articles

    [1]Shangdan XIE, Qunchao HU, Haiyan ZHU. Research advances in the treatment of cervical cancer with liver metastasis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1307-1311. doi: 10.12449/JCH240704
    [2]Xiangyu WANG, Jinhong CHEN. Treatment of metastatic liver cancer： Current status and future perspectives[J]. Journal of Clinical Hepatology, 2024, 40(7): 1289-1294. doi: 10.12449/JCH240701
    [3]Jinyuan TANG, Chenfenglin YANG, Dongle LIANG, Yuhao LUO. Role of exosomes in intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 181-186. doi: 10.12449/JCH240130
    [4]Qihui ZENG, Fuyu LI. Feasibility and safety of laparoscopic radical surgery for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2358-2360. doi: 10.12449/JCH241203
    [5]Di HU, Jintao HUANG, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Advances in the diagnosis and treatment of intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2024, 40(7): 1470-1476. doi: 10.12449/JCH240728
    [6]Yihang WANG, Jiangtao LI. Advances in treatment decision-making for extrahepatic recurrence of intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2361-2365. doi: 10.12449/JCH241204
    [7]Anfeng SI, Zhengqing LEI, Zhangjun CHENG. Several issues in the surgical treatment of intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2351-2357. doi: 10.12449/JCH241202
    [8]Chun WEI, Yu LIU, Bo LI, Ou JIANG. Efficacy and safety of microwave ablation combined with systemic chemotherapy in treatment of recurrent intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(7): 1609-1616. doi: 10.3969/j.issn.1001-5256.2023.07.015
    [9]Xingshu ZHU, Pengfei CHEN, Mengfan ZHANG, Fangzheng LI, Jinwei CHEN, Wenguang ZHANG, Xuhua DUAN, Jianzhuang REN, Xinwei HAN. Efficacy and safety of 125I intraluminal irradiation combined with lenvatinib in treatment of progressive extrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(10): 2406-2412. doi: 10.3969/j.issn.1001-5256.2023.10.019
    [10]Xiaofang ZHAO, Aimin ZHANG, Wengang LI, Jing SUN, Xiaoyun CHANG, Tao ZHANG, Weiping HE, Xuezhang DUAN. Efficacy and safety of stereotactic body radiation therapy in treatment of patients with unresectable cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2657-2662. doi: 10.3969/j.issn.1001-5256.2023.11.021
    [11]Zhiwen LIN, Hongzhi LIU, Yongyi ZENG, Kecan LIN. Hotspots and advances in neoadjuvant therapy for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(9): 2031-2038. doi: 10.3969/j.issn.1001-5256.2023.09.002
    [12]Lixin ZHANG, Jianjiao ZHU, Gang YANG, Jingdong LI. Features of lymph node metastasis and nerve plexus invasion in hilar cholangiocarcinoma and key points for dissection[J]. Journal of Clinical Hepatology, 2023, 39(9): 2045-2048. doi: 10.3969/j.issn.1001-5256.2023.09.004
    [13]Jiachao ZHANG, Zhensheng ZHANG, Pingping CHEN, Rong TANG, Yongchao ZENG, Qizhao LI. Complete remission after comprehensive treatment of lung metastases following liver cancer surgery: A case report[J]. Journal of Clinical Hepatology, 2021, 37(6): 1432-1434. doi: 10.3969/j.issn.1001-5256.2021.06.044
    [14]Shanshan CHEN, Wei LI. Research advances in non-surgical treatment of distal cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(7): 1729-1732. doi: 10.3969/j.issn.1001-5256.2021.07.053
    [15]Wenhua YOU, Yuan LIANG, Ling LYU. Pathogenesis and clinical translation of intrahepatic cholangiocarcinoma in the era of precision medicine[J]. Journal of Clinical Hepatology, 2021, 37(4): 935-938. doi: 10.3969/j.issn.1001-5256.2021.04.045
    [16]Ge JianKang, Wang Yao, Wang Lei, Zhu MingYan, Lin XiDa, Lu LingLing. Dual-phenotype hepatocellular carcinoma presenting as cholangiocarcinoma on imaging: A case report[J]. Journal of Clinical Hepatology, 2020, 36(4): 883-884. doi: 10.3969/j.issn.1001-5256.2020.04.037
    [17]Xia Long, Xia YiJun, Zhang Lei, Zhu ShuGuang, Wu HuiJun, Li Hua, Chen GuiHua. Diagnosis and treatment of intrahepatic cholangiocarcinoma: Current status and thoughts[J]. Journal of Clinical Hepatology, 2020, 36(10): 2380-2385. doi: 10.3969/j.issn.1001-5256.2020.10.048
    [18]Bo Lun, Zhang Qiong, Wang XiangXu, Pan Wei, Zhang HongMei. Role of the VEGF/VEGFR pathways in the development,progression,and treatment of cholangiocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1866-1869. doi: 10.3969/j.issn.1001-5256.2020.08.041
    [19]Zhang HeYue, Ju MingGuang, Xu Feng. Current status and prospect of prophylactic lymph node dissection for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2020, 36(9): 2103-2106. doi: 10.3969/j.issn.1001-5256.2020.09.044
    [20]Chen Kai, Zhao Ji, Deng XiaoFan, Yang HongJi. A rare case of hepatocellular carcinoma featuring association with the pancreas and duodenum, and giant cells in the portacaval space and the post-superior mesenteric artery region[J]. Journal of Clinical Hepatology, 2012, 28(11): 865-866.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(1)

    1. 孙江阳，蔡常春. 肝内胆管癌的手术治疗相关问题浅谈. 腹部外科. 2023(05): 343-347+360 .

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 26.2 %FULLTEXT: 26.2 %META: 70.0 %META: 70.0 %PDF: 3.9 %PDF: 3.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.5 %其他: 6.5 %其他: 1.3 %其他: 1.3 %Australia: 0.2 %Australia: 0.2 %Baden: 0.1 %Baden: 0.1 %Bass Hill: 0.0 %Bass Hill: 0.0 %Canada: 0.2 %Canada: 0.2 %Central District: 0.1 %Central District: 0.1 %China: 0.5 %China: 0.5 %Hollywood: 0.0 %Hollywood: 0.0 %India: 0.1 %India: 0.1 %Japan: 0.2 %Japan: 0.2 %Korea Republic of: 0.1 %Korea Republic of: 0.1 %Rochester: 0.0 %Rochester: 0.0 %Russian Federation: 0.0 %Russian Federation: 0.0 %Saitama: 0.0 %Saitama: 0.0 %Seattle: 0.0 %Seattle: 0.0 %Switzerland: 0.0 %Switzerland: 0.0 %Taiwan, China: 0.1 %Taiwan, China: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.6 %[]: 0.6 %三亚: 0.0 %三亚: 0.0 %三明: 0.0 %三明: 0.0 %上海: 4.5 %上海: 4.5 %东京: 0.1 %东京: 0.1 %东莞: 0.3 %东莞: 0.3 %中卫: 2.2 %中卫: 2.2 %中山: 0.1 %中山: 0.1 %临汾: 0.1 %临汾: 0.1 %丽水: 0.1 %丽水: 0.1 %乌鲁木齐: 0.5 %乌鲁木齐: 0.5 %亚特兰大: 0.0 %亚特兰大: 0.0 %亳州: 0.0 %亳州: 0.0 %伊春: 0.1 %伊春: 0.1 %伊犁: 0.0 %伊犁: 0.0 %休斯敦: 0.0 %休斯敦: 0.0 %佛山: 0.1 %佛山: 0.1 %保定: 0.0 %保定: 0.0 %保山: 0.1 %保山: 0.1 %兰州: 0.5 %兰州: 0.5 %加利福尼亚: 0.0 %加利福尼亚: 0.0 %北京: 13.7 %北京: 13.7 %南京: 0.8 %南京: 0.8 %南宁: 0.5 %南宁: 0.5 %南平: 0.1 %南平: 0.1 %南昌: 0.1 %南昌: 0.1 %南阳: 0.0 %南阳: 0.0 %台北: 0.2 %台北: 0.2 %台州: 1.0 %台州: 1.0 %合肥: 0.3 %合肥: 0.3 %吉安: 0.1 %吉安: 0.1 %吉林: 0.3 %吉林: 0.3 %吕梁: 0.0 %吕梁: 0.0 %呼和浩特: 0.3 %呼和浩特: 0.3 %咸阳: 0.0 %咸阳: 0.0 %哈尔滨: 0.3 %哈尔滨: 0.3 %哥伦布: 0.1 %哥伦布: 0.1 %唐山: 0.0 %唐山: 0.0 %商丘: 0.0 %商丘: 0.0 %商洛: 0.0 %商洛: 0.0 %喀什: 0.0 %喀什: 0.0 %嘉兴: 0.0 %嘉兴: 0.0 %四平: 0.1 %四平: 0.1 %埃克塞特: 0.0 %埃克塞特: 0.0 %多伦多: 0.0 %多伦多: 0.0 %大庆: 0.0 %大庆: 0.0 %大连: 0.3 %大连: 0.3 %大阪: 0.0 %大阪: 0.0 %天津: 0.8 %天津: 0.8 %太原: 0.3 %太原: 0.3 %孝感: 0.0 %孝感: 0.0 %安康: 0.2 %安康: 0.2 %安顺: 0.0 %安顺: 0.0 %宜宾: 0.0 %宜宾: 0.0 %宜春: 0.1 %宜春: 0.1 %宣城: 0.1 %宣城: 0.1 %宿迁: 0.0 %宿迁: 0.0 %密蘇里城: 0.0 %密蘇里城: 0.0 %屯昌: 0.0 %屯昌: 0.0 %岳阳: 0.0 %岳阳: 0.0 %巴音郭楞: 0.0 %巴音郭楞: 0.0 %布雷登顿: 0.0 %布雷登顿: 0.0 %常德: 0.2 %常德: 0.2 %平顶山: 0.1 %平顶山: 0.1 %广州: 0.9 %广州: 0.9 %廊坊: 0.0 %廊坊: 0.0 %开封: 0.1 %开封: 0.1 %张家口: 2.0 %张家口: 2.0 %张家界: 0.0 %张家界: 0.0 %徐州: 0.2 %徐州: 0.2 %德阳: 0.0 %德阳: 0.0 %悉尼: 0.0 %悉尼: 0.0 %惠州: 0.0 %惠州: 0.0 %意法半: 0.1 %意法半: 0.1 %成都: 0.5 %成都: 0.5 %扬州: 0.0 %扬州: 0.0 %承德: 0.1 %承德: 0.1 %攀枝花: 0.0 %攀枝花: 0.0 %文山: 0.0 %文山: 0.0 %新余: 0.0 %新余: 0.0 %新加坡: 0.1 %新加坡: 0.1 %新南威尔士: 0.0 %新南威尔士: 0.0 %新竹: 0.0 %新竹: 0.0 %无锡: 0.1 %无锡: 0.1 %昆明: 0.4 %昆明: 0.4 %昌吉: 0.0 %昌吉: 0.0 %晋城: 0.1 %晋城: 0.1 %朝阳: 0.2 %朝阳: 0.2 %来宾: 0.0 %来宾: 0.0 %杭州: 1.0 %杭州: 1.0 %枣庄: 0.0 %枣庄: 0.0 %查塔努加: 0.0 %查塔努加: 0.0 %柳州: 0.1 %柳州: 0.1 %桂林: 0.0 %桂林: 0.0 %榆林: 0.0 %榆林: 0.0 %武汉: 0.5 %武汉: 0.5 %永州: 0.0 %永州: 0.0 %江门: 0.2 %江门: 0.2 %沈阳: 0.2 %沈阳: 0.2 %河池: 0.0 %河池: 0.0 %河源: 0.0 %河源: 0.0 %法兰克福: 0.0 %法兰克福: 0.0 %波士顿: 0.0 %波士顿: 0.0 %泰州: 0.0 %泰州: 0.0 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.2 %洛阳: 0.2 %济南: 0.4 %济南: 0.4 %济宁: 0.1 %济宁: 0.1 %海口: 0.3 %海口: 0.3 %海得拉巴: 0.0 %海得拉巴: 0.0 %淄博: 0.0 %淄博: 0.0 %淮南: 0.0 %淮南: 0.0 %深圳: 1.2 %深圳: 1.2 %温州: 0.1 %温州: 0.1 %渭南: 0.2 %渭南: 0.2 %湖州: 0.2 %湖州: 0.2 %湘潭: 0.1 %湘潭: 0.1 %湘西: 0.0 %湘西: 0.0 %湛江: 0.2 %湛江: 0.2 %滨州: 0.0 %滨州: 0.0 %漯河: 0.1 %漯河: 0.1 %漳州: 0.3 %漳州: 0.3 %潍坊: 0.0 %潍坊: 0.0 %烟台: 0.0 %烟台: 0.0 %玉林: 0.1 %玉林: 0.1 %班加罗尔: 0.0 %班加罗尔: 0.0 %盐城: 0.1 %盐城: 0.1 %石嘴山: 0.1 %石嘴山: 0.1 %石家庄: 0.7 %石家庄: 0.7 %福州: 0.5 %福州: 0.5 %秦皇岛: 0.1 %秦皇岛: 0.1 %红河: 0.0 %红河: 0.0 %纽约: 0.1 %纽约: 0.1 %绵阳: 0.0 %绵阳: 0.0 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %自贡: 0.0 %自贡: 0.0 %芒廷维尤: 23.2 %芒廷维尤: 23.2 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.3 %苏州: 0.3 %荆州: 0.0 %荆州: 0.0 %莫斯科: 0.9 %莫斯科: 0.9 %菏泽: 0.0 %菏泽: 0.0 %葵涌: 0.1 %葵涌: 0.1 %衡水: 0.1 %衡水: 0.1 %衢州: 0.3 %衢州: 0.3 %西宁: 10.0 %西宁: 10.0 %西安: 0.8 %西安: 0.8 %许昌: 0.1 %许昌: 0.1 %贵阳: 0.6 %贵阳: 0.6 %赣州: 0.1 %赣州: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 0.7 %运城: 0.7 %通化: 0.0 %通化: 0.0 %通辽: 0.0 %通辽: 0.0 %邯郸: 0.0 %邯郸: 0.0 %郑州: 0.9 %郑州: 0.9 %鄂尔多斯: 0.0 %鄂尔多斯: 0.0 %鄂州: 0.1 %鄂州: 0.1 %酒泉: 0.1 %酒泉: 0.1 %重庆: 0.9 %重庆: 0.9 %金华: 0.0 %金华: 0.0 %铁岭: 0.2 %铁岭: 0.2 %银川: 0.2 %银川: 0.2 %锡林郭勒盟: 0.0 %锡林郭勒盟: 0.0 %镇江: 0.1 %镇江: 0.1 %长春: 0.7 %长春: 0.7 %长沙: 2.5 %长沙: 2.5 %长治: 0.1 %长治: 0.1 %阜阳: 0.0 %阜阳: 0.0 %阿坝: 0.0 %阿坝: 0.0 %阿萨姆邦: 0.0 %阿萨姆邦: 0.0 %青岛: 0.6 %青岛: 0.6 %香港特别行政区: 0.1 %香港特别行政区: 0.1 %驻马店: 0.0 %驻马店: 0.0 %黄冈: 0.1 %黄冈: 0.1 %黔南: 0.0 %黔南: 0.0 %龙岩: 0.0 %龙岩: 0.0 %其他其他AustraliaBadenBass HillCanadaCentral DistrictChinaHollywoodIndiaJapanKorea Republic ofRochesterRussian FederationSaitamaSeattleSwitzerlandTaiwan, ChinaUnited States[]三亚三明上海东京东莞中卫中山临汾丽水乌鲁木齐亚特兰大亳州伊春伊犁休斯敦佛山保定保山兰州加利福尼亚北京南京南宁南平南昌南阳台北台州合肥吉安吉林吕梁呼和浩特咸阳哈尔滨哥伦布唐山商丘商洛喀什嘉兴四平埃克塞特多伦多大庆大连大阪天津太原孝感安康安顺宜宾宜春宣城宿迁密蘇里城屯昌岳阳巴音郭楞布雷登顿常德平顶山广州廊坊开封张家口张家界徐州德阳悉尼惠州意法半成都扬州承德攀枝花文山新余新加坡新南威尔士新竹无锡昆明昌吉晋城朝阳来宾杭州枣庄查塔努加柳州桂林榆林武汉永州江门沈阳河池河源法兰克福波士顿泰州洛杉矶洛阳济南济宁海口海得拉巴淄博淮南深圳温州渭南湖州湘潭湘西湛江滨州漯河漳州潍坊烟台玉林班加罗尔盐城石嘴山石家庄福州秦皇岛红河纽约绵阳美国伊利诺斯芝加哥自贡芒廷维尤芝加哥苏州荆州莫斯科菏泽葵涌衡水衢州西宁西安许昌贵阳赣州赤峰运城通化通辽邯郸郑州鄂尔多斯鄂州酒泉重庆金华铁岭银川锡林郭勒盟镇江长春长沙长治阜阳阿坝阿萨姆邦青岛香港特别行政区驻马店黄冈黔南龙岩

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1467) PDF downloads(81) Cited by(2)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1835]YesterdayPV[3810]TodayIP[1655]TodayPV[3233]Online[154]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return